<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564902</url>
  </required_header>
  <id_info>
    <org_study_id>CHRY1</org_study_id>
    <secondary_id>IRB 07-046</secondary_id>
    <nct_id>NCT00564902</nct_id>
  </id_info>
  <brief_title>The Zeaxanthin and Visual Function Study</brief_title>
  <acronym>ZVF</acronym>
  <official_title>Randomized, Double Blind, Lutein Controlled Study of Zeaxanthin and Visual Function in Atrophic Age Related Macular Degeneration Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chrysantis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kowa Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>IMAGE TECHNOLOGIES INC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chrysantis, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate if supplementation of zeaxanthin (with or without Lutein) is beneficial to
      patients with early and moderate Atrophic Age Related Macular Degeneration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate whether or not zeaxanthin supplementation raises macular pigment optical density
      (MPOD). Previous research has shown MPOD to mirror visual benefits for patients with age
      related atrophic macular degeneration (AMD) having visual symptoms (decreased visual acuity,
      contrast sensitivity, photostress glare recovery and National Eye Institute Visual Function
      Questionnaire 25 scores), but lower risk National Eye Institute (NEI) / Age Related Eye
      Disease Study (AREDS) characteristics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macular Pigment Optical Density</measure>
    <time_frame>4 months</time_frame>
    <description>Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering LED's and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated. The method has good repeatability (r = 0.97) and the data are comparable with an objective optical method based on retinal reflectometry (r = 0.78).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Macular Pigment Optical Density</measure>
    <time_frame>8 months</time_frame>
    <description>Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering LED's and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated. The method has good repeatability (r = 0.97) and the data are comparable with an objective optical method based on retinal reflectometry (r = 0.78).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Macular Pigment Optical Density</measure>
    <time_frame>12 months</time_frame>
    <description>Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering light emitting diodes and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SHAPE Discrimination</measure>
    <time_frame>12 months</time_frame>
    <description>We determined the target deformation detection thresholds, or amplitude of the minimum detectable distortion of a 1 degree foveal circular target. The peak spatial frequency of RF (radial frequency) patterns was 5 cyc/deg; the radial modulation frequency was 8 cyc/360°; mean radii were 0.5°, 1°, 2.0°, or 2.5°; and stimulus contrast was 80%. The highest % modulation score possible is 0.13 while the easiest (lowest score) was 10% modulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Treatment Diabetic Retinopathy Study Distance Visual Acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Black and 10% contrast near reading visual acuity was assessed with a Colenbrander Mixed Contrast Reading Card with LogMAR letters (#4031, Precision Vision, LaSalle, Illinois). We determined single letter acuity on an ordinal VAS (Visual Acuity Scale). The largest letters were 0.05 LogMAR with a VAS = 35 while the most difficult smallest letters were LogMar 1.25 or VAS 105. The test card was held at 40 cm with best monocular refraction, and both low and high contrast letter acuity were assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glare Recovery</measure>
    <time_frame>12 Months</time_frame>
    <description>Photostress glare recovery test involves exposing an individual eye to intense light, or retinal bleach, for a set duration of time and measuring the time taken for visual acuity to recover to a predetermined level. Glare photo-stress recovery (in seconds) following 30 seconds of continuous retinal bleach, was assessed using 2 line supra-threshold low contrast randomly presented Landolt Cs using the KOWA AS14B Night Vision Tester (KOWA Optimed, Tokyo, Japan).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Sensitivity Function Photopic Distance</measure>
    <time_frame>12 Months</time_frame>
    <description>Distance photopic contrast sensitivity function (CSF) at 5 spatial frequencies (1.5, 3, 6, 12 &amp; 20 cc/deg) was determined with the Functional Vision Analyzer® (Stereo Optical Co, Inc, Chicago, IL). Contrast sensitivity readings are shown as a curve. Visual acuity is plotted along the horizontal axis and contrast sensitivity along the vertical axis. Among the normally sighted people, both visual acuity and contrast sensitivity have a wide range of variation.Low population CSF is 0-200 units; normal population CSF is 200-300 units and suprathreshold CSF is 300+ units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6.5 Degrees Tritan Threshold</measure>
    <time_frame>12 months</time_frame>
    <description>The ChromaTest© is a computerized psychophysical test of protan and tritan color thresholds against age-corrected data. The computer finds the endpoint of the test by a Modified Binary Search method; if response is correct, on the next presentation the color difference between letter and background is halved. If response is incorrect, the color -contrast is doubled. Incorrect responses prolong the test, but do not influence the final threshold. This method of determining thresholds leads to finite steps which reach a plateau at the color contrast sensitivity threshold.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100% Kinetic Field</measure>
    <time_frame>12 Months</time_frame>
    <description>Scotomas within the central 20 degree central macula visual field sensitivity was assessed at 5 contrast levels (20, 40, 60, 80, and full contrast). A yellow wavelength stimulus avoided confounding by the lens. Subjects outlined the boundaries of their scotoma(s) on an area-integrating and recording touch flat- screen RGB monitor displaying a central fixation point and movable horizontal/vertical raster lines. The computer calculated summed area of the scotoma(s) with arbitrary scaling from 6000 (dense scotoma) to 0 relative units (absence of scotoma).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <condition>Cognition Disorders</condition>
  <arm_group>
    <arm_group_label>Lutein</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>9 mg of Lutein for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zeaxanthin and Lutein</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zeaxanthin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3R 3'R Zeaxanthin 8 mg per day during 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3R 3'R Zeaxanthin</intervention_name>
    <description>8 mg per day during 12 months</description>
    <arm_group_label>Zeaxanthin</arm_group_label>
    <other_name>EZEyes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lutein</intervention_name>
    <description>9 mg of Lutein during 12 months</description>
    <arm_group_label>Lutein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lutein and Zeaxanthin</intervention_name>
    <description>8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months</description>
    <arm_group_label>Zeaxanthin and Lutein</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of atrophic AMD (ICD9 362.51) by stereo bio-ophthalmoscopy and at least one
             vision degrading visual-psychophysical abnormality associated with AMD in one or both
             eyes.

          -  clear non-lenticular ocular media (cornea, aqueous and vitreous)

          -  free of advanced glaucoma and diabetes or any other ocular or systemic disease that
             could affect central or parafoveal macula visual function

        Exclusion Criteria:

          -  high risk retinal characteristics for advanced AMD or advanced AMD for which existing
             medical / surgical options are available

          -  presence of ophthalmologically significant active exudative, AMD pathology by
             fluorescein angiography but also a single large drusen, &gt;15, multiple intermediate
             drusen, parafoveal geographic atrophy or loss of vision in one eye due to advanced AMD

          -  recent (within 6 months) cataract or retinal surgery

          -  taking photosensitizing drugs such as phenothiazines and chloroquine

          -  having taken lutein or zeaxanthin supplements within the past six months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Richer, Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Chicago VA Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Stiles, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>North Chicago VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Chicago VA Medical Center</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Delcourt C, Carrière I, Delage M, Barberger-Gateau P, Schalch W; POLA Study Group. Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA Study. Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2329-35.</citation>
    <PMID>16723441</PMID>
  </reference>
  <reference>
    <citation>Schalch W, Cohn W, Barker FM, Köpcke W, Mellerio J, Bird AC, Robson AG, Fitzke FF, van Kuijk FJ. Xanthophyll accumulation in the human retina during supplementation with lutein or zeaxanthin - the LUXEA (LUtein Xanthophyll Eye Accumulation) study. Arch Biochem Biophys. 2007 Feb 15;458(2):128-35. Epub 2006 Nov 7.</citation>
    <PMID>17084803</PMID>
  </reference>
  <reference>
    <citation>Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tsipursky M, Nyland J. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry. 2004 Apr;75(4):216-30.</citation>
    <PMID>15117055</PMID>
  </reference>
  <reference>
    <citation>Richer S, Devenport J, Lang JC. LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry. 2007 May;78(5):213-9.</citation>
    <PMID>17478338</PMID>
  </reference>
  <reference>
    <citation>Leung IY, Sandstrom MM, Zucker CL, Neuringer M, Max Snodderly D. Nutritional manipulation of primate retinas. IV. Effects of n--3 fatty acids, lutein, and zeaxanthin on S-cones and rods in the foveal region. Exp Eye Res. 2005 Nov;81(5):513-29.</citation>
    <PMID>15916761</PMID>
  </reference>
  <reference>
    <citation>Neuringer M, Sandstrom MM, Johnson EJ, Snodderly DM. Nutritional manipulation of primate retinas, I: effects of lutein or zeaxanthin supplements on serum and macular pigment in xanthophyll-free rhesus monkeys. Invest Ophthalmol Vis Sci. 2004 Sep;45(9):3234-43.</citation>
    <PMID>15326146</PMID>
  </reference>
  <reference>
    <citation>Akbaraly NT, Faure H, Gourlet V, Favier A, Berr C. Plasma carotenoid levels and cognitive performance in an elderly population: results of the EVA Study. J Gerontol A Biol Sci Med Sci. 2007 Mar;62(3):308-16.</citation>
    <PMID>17389729</PMID>
  </reference>
  <reference>
    <citation>Thomson LR, Toyoda Y, Langner A, Delori FC, Garnett KM, Craft N, Nichols CR, Cheng KM, Dorey CK. Elevated retinal zeaxanthin and prevention of light-induced photoreceptor cell death in quail. Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3538-49.</citation>
    <PMID>12407166</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2007</study_first_submitted>
  <study_first_submitted_qc>November 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2007</study_first_posted>
  <results_first_submitted>November 11, 2011</results_first_submitted>
  <results_first_submitted_qc>March 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 29, 2012</results_first_posted>
  <last_update_submitted>March 28, 2012</last_update_submitted>
  <last_update_submitted_qc>March 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular Pigment Optical Density</keyword>
  <keyword>Skin Carotenoids</keyword>
  <keyword>Lipofuscin</keyword>
  <keyword>Photostress (Glare Recovery)</keyword>
  <keyword>Visual Field Progression</keyword>
  <keyword>Contrast Sensitivity</keyword>
  <keyword>Color Vision</keyword>
  <keyword>Cognitive Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were patients in the Ophthalmology/Optometry Clinic North Chicago DVA Medical Center (now the James A. Lovell Federal Health Center)with early and moderate AMD retinopathy up to, but not including,high risk NEI AREDS retinopathy.</recruitment_details>
      <pre_assignment_details>No enrolled participant was excluded before assignment to groups. Patients were asked to continue with their normal diet and were asked not to take any dietary supplement containing lutein (or zeaxanthin) beyond the 250 ug (1/4mg) commonly found in pabulum Centrum® type vitamins.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lutein</title>
          <description>Lutein 9 mg per day</description>
        </group>
        <group group_id="P2">
          <title>Lutein Zeaxanthin</title>
          <description>3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months</description>
        </group>
        <group group_id="P3">
          <title>Zeaxanthin</title>
          <description>3R 3'R Zeaxanthin 8 mg per day during 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>4 Months</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>8 Months</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>12 Months</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lutein</title>
          <description>Lutein 9 mg per day</description>
        </group>
        <group group_id="B2">
          <title>Lutein Zeaxanthin</title>
          <description>3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months</description>
        </group>
        <group group_id="B3">
          <title>Zeaxanthin</title>
          <description>3R 3'R Zeaxanthin 8 mg per day during 12 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.9" spread="9"/>
                    <measurement group_id="B2" value="75.8" spread="9"/>
                    <measurement group_id="B3" value="74.4" spread="11"/>
                    <measurement group_id="B4" value="74.9" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Macular Pigment Optical Density</title>
          <description>Foveal 1 degree estimated central macular pigment density evaluated with the QuantifEye (ZeaVision, Inc., Chesterfield, Missouri),a modified heterochromic flicker photometer (HFP). The MPOD value is derived by taking the logarithm of the ratio between blue and green luminance measured centrally and peripherally. MPOD varies widely between individuals. Low MPOD is 0 – 0.20 density units (du), normal MPOD is 0.20 – 0.50 du and high MPOD is any value above 0.50 du.</description>
          <units>Density units of macular pigment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.37" spread="0.05"/>
                    <measurement group_id="B2" value="0.29" spread="0.06"/>
                    <measurement group_id="B3" value="0.35" spread="0.04"/>
                    <measurement group_id="B4" value="0.33" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Early Treatment Diabetic Retinopathy Study distance visual acuity</title>
          <description>Black and 10% contrast near reading visual acuity was assessed with a Colenbrander Mixed Contrast Reading Card with LogMAR letters (#4031, Precision Vision, LaSalle, Illinois). We determined single letter acuity on an ordinal VAS (Visual Acuity Scale). The largest letters were 0.05 LogMAR with a VAS = 35 while the most difficult smallest letters were LogMar 1.25 or VAS 105. The test card was held at 40 cm with best monocular refraction, and both low and high contrast letter acuity were assessed.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.3" spread="8"/>
                    <measurement group_id="B2" value="86.8" spread="12"/>
                    <measurement group_id="B3" value="88.3" spread="10"/>
                    <measurement group_id="B4" value="88.7" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glare Recovery</title>
          <description>Photostress glare recovery test involves exposing an individual eye to intense light, or retinal bleach, for a set duration of time and measuring the time taken for visual acuity to recover to a predetermined level. (Margrain 2002) Glare photo-stress recovery (in seconds) following 30 seconds of continuous retinal bleach, was assessed using 2 line supra-threshold low contrast randomly presented Landolt Cs using the KOWA AS14B Night Vision Tester (KOWA Optimed, Tokyo, Japan).</description>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.9" spread="16"/>
                    <measurement group_id="B2" value="35.6" spread="6"/>
                    <measurement group_id="B3" value="26.7" spread="5"/>
                    <measurement group_id="B4" value="34.1" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Contrast Sensitivity Function Photopic Distance</title>
          <description>Distance photopic contrast sensitivity function (CSF) at 5 spatial frequencies (1.5, 3, 6, 12 &amp; 20 cc/deg) was determined with the Functional Vision Analyzer® (Stereo Optical Co, Inc, Chicago, IL). Contrast sensitivity readings are shown as a curve. Visual acuity is plotted along the horizontal axis and contrast sensitivity along the vertical axis. Among the normally sighted people, both visual acuity and contrast sensitivity have a wide range of variation.Low population CSF is 0-200 units; normal population CSF is 200-300 units and suprathreshold CSF is 300+ units.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212" spread="34"/>
                    <measurement group_id="B2" value="204" spread="30"/>
                    <measurement group_id="B3" value="201" spread="22"/>
                    <measurement group_id="B4" value="204" spread="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Shape Discrimination</title>
          <description>We determined the target deformation detection thresholds, or amplitude of the minimum detectable distortion of a 1 degree foveal circular target. The peak spatial frequency of RF (radial frequency) patterns was 5 cyc/deg; the radial modulation frequency was 8 cyc/360°; mean radii were 0.5°, 1°, 2.0°, or 2.5°; and stimulus contrast was 80%. The highest % modulation score possible is 0.13 while the easiest (lowest score) was 10% modulation.</description>
          <units>% modulation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.7" spread="0.2"/>
                    <measurement group_id="B2" value="0.7" spread="0.1"/>
                    <measurement group_id="B3" value="1" spread="0.2"/>
                    <measurement group_id="B4" value="0.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>6.5 degrees Tritan threshold</title>
          <description>The ChromaTest© is a computerized psychophysical test of protan and tritan color thresholds against age-corrected data. The computer finds the endpoint of the test by a Modified Binary Search method; if response is correct, on the next presentation the color difference between letter and background is halved. If response is incorrect, the color -contrast is doubled. Incorrect responses prolong the test, but do not influence the final threshold. This method of determining thresholds leads to finite steps which reach a plateau at the color contrast sensitivity threshold.</description>
          <units>(dB)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="4"/>
                    <measurement group_id="B2" value="8.6" spread="12"/>
                    <measurement group_id="B3" value="6" spread="9"/>
                    <measurement group_id="B4" value="6.9" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>100% Kinetic Field</title>
          <description>Scotomas within the central 20 degree central macula visual field sensitivity were assessed at 5 contrast levels (20, 40, 60, 80, and full contrast). A yellow wavelength stimulus avoided confounding by the lens. Subjects outline the boundaries of their scotoma(s) on an area-integrating and recording touch flat- screen RGB monitor displaying a central fixation point and movable horizontal/vertical raster lines. The computer calculates summed area of the scotoma(s) with arbitrary scaling from 6000 (dense scotoma) to 0 relative units (absence of scotoma).</description>
          <units>Units on a scale (0 to 6000)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5514" spread="2074"/>
                    <measurement group_id="B2" value="1717" spread="765"/>
                    <measurement group_id="B3" value="2649" spread="750"/>
                    <measurement group_id="B4" value="2738" spread="4471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Macular Pigment Optical Density</title>
        <description>Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering LED's and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated. The method has good repeatability (r = 0.97) and the data are comparable with an objective optical method based on retinal reflectometry (r = 0.78).</description>
        <time_frame>4 months</time_frame>
        <population>All participants in all arms were tested</population>
        <group_list>
          <group group_id="O1">
            <title>Lutein</title>
            <description>Lutein 9 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Lutein Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months</description>
          </group>
          <group group_id="O3">
            <title>Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg per day during 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Macular Pigment Optical Density</title>
          <description>Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering LED's and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated. The method has good repeatability (r = 0.97) and the data are comparable with an objective optical method based on retinal reflectometry (r = 0.78).</description>
          <population>All participants in all arms were tested</population>
          <units>Density units of Macular Pigment (du)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread=".05"/>
                    <measurement group_id="O2" value="0.38" spread=".06"/>
                    <measurement group_id="O3" value="0.42" spread=".04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SHAPE Discrimination</title>
        <description>We determined the target deformation detection thresholds, or amplitude of the minimum detectable distortion of a 1 degree foveal circular target. The peak spatial frequency of RF (radial frequency) patterns was 5 cyc/deg; the radial modulation frequency was 8 cyc/360°; mean radii were 0.5°, 1°, 2.0°, or 2.5°; and stimulus contrast was 80%. The highest % modulation score possible is 0.13 while the easiest (lowest score) was 10% modulation.</description>
        <time_frame>12 months</time_frame>
        <population>Eyes of all participants still in the trial were measured</population>
        <group_list>
          <group group_id="O1">
            <title>Lutein</title>
            <description>Lutein 9 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Lutein Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months</description>
          </group>
          <group group_id="O3">
            <title>Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg per day during 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>SHAPE Discrimination</title>
          <description>We determined the target deformation detection thresholds, or amplitude of the minimum detectable distortion of a 1 degree foveal circular target. The peak spatial frequency of RF (radial frequency) patterns was 5 cyc/deg; the radial modulation frequency was 8 cyc/360°; mean radii were 0.5°, 1°, 2.0°, or 2.5°; and stimulus contrast was 80%. The highest % modulation score possible is 0.13 while the easiest (lowest score) was 10% modulation.</description>
          <population>Eyes of all participants still in the trial were measured</population>
          <units>% modulation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread=".24"/>
                    <measurement group_id="O2" value="0.6" spread="0.25"/>
                    <measurement group_id="O3" value="0.6" spread=".46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Treatment Diabetic Retinopathy Study Distance Visual Acuity</title>
        <description>Black and 10% contrast near reading visual acuity was assessed with a Colenbrander Mixed Contrast Reading Card with LogMAR letters (#4031, Precision Vision, LaSalle, Illinois). We determined single letter acuity on an ordinal VAS (Visual Acuity Scale). The largest letters were 0.05 LogMAR with a VAS = 35 while the most difficult smallest letters were LogMar 1.25 or VAS 105. The test card was held at 40 cm with best monocular refraction, and both low and high contrast letter acuity were assessed.</description>
        <time_frame>12 months</time_frame>
        <population>Eyes of all patients still in the trial were measured</population>
        <group_list>
          <group group_id="O1">
            <title>Lutein</title>
            <description>Lutein 9 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Lutein Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months</description>
          </group>
          <group group_id="O3">
            <title>Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg per day during 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Early Treatment Diabetic Retinopathy Study Distance Visual Acuity</title>
          <description>Black and 10% contrast near reading visual acuity was assessed with a Colenbrander Mixed Contrast Reading Card with LogMAR letters (#4031, Precision Vision, LaSalle, Illinois). We determined single letter acuity on an ordinal VAS (Visual Acuity Scale). The largest letters were 0.05 LogMAR with a VAS = 35 while the most difficult smallest letters were LogMar 1.25 or VAS 105. The test card was held at 40 cm with best monocular refraction, and both low and high contrast letter acuity were assessed.</description>
          <population>Eyes of all patients still in the trial were measured</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" spread="5.7"/>
                    <measurement group_id="O2" value="92.8" spread="5.9"/>
                    <measurement group_id="O3" value="96.8" spread="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glare Recovery</title>
        <description>Photostress glare recovery test involves exposing an individual eye to intense light, or retinal bleach, for a set duration of time and measuring the time taken for visual acuity to recover to a predetermined level. Glare photo-stress recovery (in seconds) following 30 seconds of continuous retinal bleach, was assessed using 2 line supra-threshold low contrast randomly presented Landolt Cs using the KOWA AS14B Night Vision Tester (KOWA Optimed, Tokyo, Japan).</description>
        <time_frame>12 Months</time_frame>
        <population>Eyes of all patients still in the trial were measured</population>
        <group_list>
          <group group_id="O1">
            <title>Lutein</title>
            <description>Lutein 9 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Lutein Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months</description>
          </group>
          <group group_id="O3">
            <title>Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg per day during 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Glare Recovery</title>
          <description>Photostress glare recovery test involves exposing an individual eye to intense light, or retinal bleach, for a set duration of time and measuring the time taken for visual acuity to recover to a predetermined level. Glare photo-stress recovery (in seconds) following 30 seconds of continuous retinal bleach, was assessed using 2 line supra-threshold low contrast randomly presented Landolt Cs using the KOWA AS14B Night Vision Tester (KOWA Optimed, Tokyo, Japan).</description>
          <population>Eyes of all patients still in the trial were measured</population>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="28.5"/>
                    <measurement group_id="O2" value="14.85" spread="22"/>
                    <measurement group_id="O3" value="16.65" spread="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contrast Sensitivity Function Photopic Distance</title>
        <description>Distance photopic contrast sensitivity function (CSF) at 5 spatial frequencies (1.5, 3, 6, 12 &amp; 20 cc/deg) was determined with the Functional Vision Analyzer® (Stereo Optical Co, Inc, Chicago, IL). Contrast sensitivity readings are shown as a curve. Visual acuity is plotted along the horizontal axis and contrast sensitivity along the vertical axis. Among the normally sighted people, both visual acuity and contrast sensitivity have a wide range of variation.Low population CSF is 0-200 units; normal population CSF is 200-300 units and suprathreshold CSF is 300+ units.</description>
        <time_frame>12 Months</time_frame>
        <population>Eyes of all patients still in the trial were measured</population>
        <group_list>
          <group group_id="O1">
            <title>Lutein</title>
            <description>Lutein 9 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Lutein Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months</description>
          </group>
          <group group_id="O3">
            <title>Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg per day during 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Contrast Sensitivity Function Photopic Distance</title>
          <description>Distance photopic contrast sensitivity function (CSF) at 5 spatial frequencies (1.5, 3, 6, 12 &amp; 20 cc/deg) was determined with the Functional Vision Analyzer® (Stereo Optical Co, Inc, Chicago, IL). Contrast sensitivity readings are shown as a curve. Visual acuity is plotted along the horizontal axis and contrast sensitivity along the vertical axis. Among the normally sighted people, both visual acuity and contrast sensitivity have a wide range of variation.Low population CSF is 0-200 units; normal population CSF is 200-300 units and suprathreshold CSF is 300+ units.</description>
          <population>Eyes of all patients still in the trial were measured</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310.5" spread="33.8"/>
                    <measurement group_id="O2" value="247.1" spread="35"/>
                    <measurement group_id="O3" value="254.7" spread="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6.5 Degrees Tritan Threshold</title>
        <description>The ChromaTest© is a computerized psychophysical test of protan and tritan color thresholds against age-corrected data. The computer finds the endpoint of the test by a Modified Binary Search method; if response is correct, on the next presentation the color difference between letter and background is halved. If response is incorrect, the color -contrast is doubled. Incorrect responses prolong the test, but do not influence the final threshold. This method of determining thresholds leads to finite steps which reach a plateau at the color contrast sensitivity threshold.</description>
        <time_frame>12 months</time_frame>
        <population>Eyes of all patients still in the trial were measured</population>
        <group_list>
          <group group_id="O1">
            <title>Lutein</title>
            <description>Lutein 9 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Lutein Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months</description>
          </group>
          <group group_id="O3">
            <title>Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg per day during 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>6.5 Degrees Tritan Threshold</title>
          <description>The ChromaTest© is a computerized psychophysical test of protan and tritan color thresholds against age-corrected data. The computer finds the endpoint of the test by a Modified Binary Search method; if response is correct, on the next presentation the color difference between letter and background is halved. If response is incorrect, the color -contrast is doubled. Incorrect responses prolong the test, but do not influence the final threshold. This method of determining thresholds leads to finite steps which reach a plateau at the color contrast sensitivity threshold.</description>
          <population>Eyes of all patients still in the trial were measured</population>
          <units>dB</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.46" spread="1.08"/>
                    <measurement group_id="O2" value="8.37" spread="1.39"/>
                    <measurement group_id="O3" value="3.45" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>100% Kinetic Field</title>
        <description>Scotomas within the central 20 degree central macula visual field sensitivity was assessed at 5 contrast levels (20, 40, 60, 80, and full contrast). A yellow wavelength stimulus avoided confounding by the lens. Subjects outlined the boundaries of their scotoma(s) on an area-integrating and recording touch flat- screen RGB monitor displaying a central fixation point and movable horizontal/vertical raster lines. The computer calculated summed area of the scotoma(s) with arbitrary scaling from 6000 (dense scotoma) to 0 relative units (absence of scotoma).</description>
        <time_frame>12 Months</time_frame>
        <population>Eyes of all patients still in the trial were measured</population>
        <group_list>
          <group group_id="O1">
            <title>Lutein</title>
            <description>Lutein 9 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Lutein Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months</description>
          </group>
          <group group_id="O3">
            <title>Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg per day during 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>100% Kinetic Field</title>
          <description>Scotomas within the central 20 degree central macula visual field sensitivity was assessed at 5 contrast levels (20, 40, 60, 80, and full contrast). A yellow wavelength stimulus avoided confounding by the lens. Subjects outlined the boundaries of their scotoma(s) on an area-integrating and recording touch flat- screen RGB monitor displaying a central fixation point and movable horizontal/vertical raster lines. The computer calculated summed area of the scotoma(s) with arbitrary scaling from 6000 (dense scotoma) to 0 relative units (absence of scotoma).</description>
          <population>Eyes of all patients still in the trial were measured</population>
          <units>Units on a scale (0 to 6000)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2704" spread="1745"/>
                    <measurement group_id="O2" value="2207" spread="210"/>
                    <measurement group_id="O3" value="1129" spread="650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Macular Pigment Optical Density</title>
        <description>Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering LED's and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated. The method has good repeatability (r = 0.97) and the data are comparable with an objective optical method based on retinal reflectometry (r = 0.78).</description>
        <time_frame>8 months</time_frame>
        <population>All participants in all arms were tested</population>
        <group_list>
          <group group_id="O1">
            <title>Lutein</title>
            <description>Lutein 9 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Lutein Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months</description>
          </group>
          <group group_id="O3">
            <title>Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg per day during 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Macular Pigment Optical Density</title>
          <description>Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering LED's and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated. The method has good repeatability (r = 0.97) and the data are comparable with an objective optical method based on retinal reflectometry (r = 0.78).</description>
          <population>All participants in all arms were tested</population>
          <units>Density units of Macular Pigment (du)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.05"/>
                    <measurement group_id="O2" value="0.44" spread="0.06"/>
                    <measurement group_id="O3" value="0.46" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Macular Pigment Optical Density</title>
        <description>Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering light emitting diodes and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated.</description>
        <time_frame>12 months</time_frame>
        <population>All participants in all arms were tested</population>
        <group_list>
          <group group_id="O1">
            <title>Lutein</title>
            <description>Lutein 9 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Lutein Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months</description>
          </group>
          <group group_id="O3">
            <title>Zeaxanthin</title>
            <description>3R 3'R Zeaxanthin 8 mg per day during 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Macular Pigment Optical Density</title>
          <description>Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering light emitting diodes and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated.</description>
          <population>All participants in all arms were tested</population>
          <units>Density units of Macular Pigment (du)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.05"/>
                    <measurement group_id="O2" value="0.52" spread="0.06"/>
                    <measurement group_id="O3" value="0.48" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>Lutein and Zeaxanthin have been used as ingredients in dietary supplements since 1994. No adverse report has ever been filed</desc>
      <group_list>
        <group group_id="E1">
          <title>Lutein</title>
          <description>Lutein 9 mg per day</description>
        </group>
        <group group_id="E2">
          <title>Lutein Zeaxanthin</title>
          <description>3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months</description>
        </group>
        <group group_id="E3">
          <title>Zeaxanthin</title>
          <description>3R 3'R Zeaxanthin 8 mg per day during 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stuart P. Richer</name_or_title>
      <organization>James A. Lovell Federal Health Care Center</organization>
      <phone>224-610-5440</phone>
      <email>Stuart.Richer1@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

